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IntroductIon of InnovatIons Into tHe German statutatory 
reImbrusment system – factors for success
Krensel M.
University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Objectives: Innovations are fundamental for progress and improvement in health 
care and medicine. In German hospitals provision of all kind of services is allowed, 
since it is not forbidden explicitly. But it is paid only if it is represented in the reim-
bursement system. For integration of innovations into this system applications must 
be addressed by each hospital which wants to provide a special innovative service in 
each year separately to the German institute for reimbursement in hospitals which 
decides about (additional) payments. The objective is to determine which factors 
influence the chance for innovations being incorporated. Results can be used by hos-
pitals to assess if certain innovations have good chances to be afforded. MethOds: 
Data about applications, their approval and assessment, number of hospitals and 
years in which approvals were made were obtained from the German institute for 
reimbursement systems in hospitals from 2005 to 2011. Innovations have been 
classified into types of methods. Applications made by medical associations and 
for orphan drugs were identified. Associations between each variable and success 
of application were calculated. In all analyses Bonferroni correction was conducted. 
Finally intercorrelation of variables was assessed. Results: Chance of integration 
was best for innovations with the following characteristics: Applications were made 
by medical associations, innovations were applied over a period of 6 years and by 
more than 100 hospitals, subjects were drugs (especially orphan drugs) and they 
belong to gynecology, oncology or cardiology and vascular medicine. Intercorrelation 
between these independent variables is also a predictor of success in some constel-
lations. cOnclusiOns: The success of integration of a new method depends on all 
analyzed variables. Therefor all of them have to be taken into account when decision 
is made about what innovation should be applied.
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Objectives: There are three main governmental stakeholders in the German 
AMNOG process: The IQWiG assesses the AMNOG drug manufacturer’s submission 
and provides advice on any additional benefit to the GBA who makes the final deci-
sion. Following confirmation of additional benefit, manufacturers start price nego-
tiations with the GKV-Spitzenverband (association of German sickness funds). The 
aim of this research is to assess the AMNOG-decisions so far. MethOds: All AMNOG 
decisions up to December 2012 were analyzed in terms of additional benefit deci-
sion, reason for additional benefit decision, reimbursed price versus manufacturer 
set price, and consistency in IQWiG-recommendation and GBA-decision. Results: 
In total AMNOG decisions of 41 drugs (60 subgroups) were identified. IQWiG rec-
ommendations were as follows: 22 cases demonstrated no additional benefit, 2 
unquantifiable benefit, 3 slight benefit, 7 significant benefit, and 7 additional benefit 
due to orphan-drug status. In 6 cases, the GBA upgraded IQWIG’s recommenda-
tions. In 3 cases it downgraded it. The following reasons were identified for GBA 
“additional benefit decisions” (multiple reasons apply for some decisions): No or 
non-quantifiable additional benefit (18 cases); no reliable clinical data (14 cases; 3 
cases no submission), wrong comparator (5 cases); additional benefit in any form 
(23 cases): mortality advantages (7 cases), orphan drug status (7 cases), morbidity 
advantages (8 cases), and QoL advantages (3 cases). The negotiated price rebates 
varied from 4.7% to 70.7% based on manufacturer set price; the rebates show limited 
correlation to the degree of additional benefit so far. cOnclusiOns: Key factors for 
positive AMNOG decisions are conducting superiority trials on mortality or at least 
morbidity/QoL against active comparators. If benefits are based on soft end-points, 
it is crucial to demonstrate these on high quality, preferably German data. Indirect 
comparisons seem to be challenged as proof of additional benefits.
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Objectives: As cost-containment pressures across Europe intensify, evidentiary 
hurdles to justify new drugs will continue to grow. Data from clinical trials alone are 
no longer adequate to meet the needs of all health care decision makers (e.g., payers 
and health technology assessment [HTA] agencies, physicians and patients), driving 
a need for robust, complementary data. However, perceived need to collect real-world 
clinical, patient-centered, and/or economic outcomes through observational studies 
varies across countries, stakeholders and organizations. The objective was to better 
understand how decision makers use observational studies to inform reimburse-
ment and/or market access decisions for new products. MethOds: Desktop research 
identified the types of observational studies most valuable for reimbursement deci-
sion making. This project extends a United States (US) payer study by conducting 
qualitative one-on-one interviews with decision makers across Europe to review the 
need for real-world evidence. Participants represented national and regional decision 
makers from several European countries, to identify specific evidence requirements 
and design attributes most accepted by payers/ HTA advisors and to understand 
how real-world evidence contributes to the value of a new drug from the decison-
makers’ perspectives. Results: Data from observational studies are used to describe 
patient segments, understand treatment patterns, resource utilization, and provide 
effectiveness data that supplement clinical trial data as well as inform risk sharing 
schemes. Observational studies help inform payer decision making but the valid-
ity and robustness of the results is often scrutinized. Publication of observational 
data in a Tier 1, peer-reviewed journal lends critical credibility to real-world study 
of economic development and a representative sample of medicines. MethOds: 
The indices were developed using the Fisher EKS method. In order to construct 
an index the products needed to be defined as like. The definition of like in this 
study was based on molecules which are deemed to deliver equivalent health 
outcomes. This is a very broad definition and allows a large number of coun-
tries and molecules to be included in the indices. Two price indices have been 
constructed. The first compares prices of mostly off-patent medicines across 56 
countries over the period from 2005 to 2011 and included 42 molecules which 
were sold in each country for the period. The second examined on-patent medi-
cines across 17 countries and 9 molecules. Results: The results showed prices 
varied significantly between regions and that prices of genericised medicines 
both fell and converged over time. For the mostly generic drugs index the regions 
from lowest to highest price were - Region of the Americas A; South-East Asian 
Region D; South-East Asian Region B; European Region B; Western Pacific Region A; 
European Region A; African Region E; European Region C; Western Pacific Region 
B; Eastern Mediterranean Region D; Region of the Americas D; Region of the 
Americas B and Eastern Mediterranean Region B. Prices tended to be similar 
within each region. These results will be presented in detail. cOnclusiOns: This 
research makes a unique contribution to our understanding of drug prices. It is 
the largest international comparison of pharmaceutical prices ever undertaken; 
employs new method to pharmaceutical pricing indices through the Fisher EKS 
method and outcomes based definitions of equivalence and examines genericised 
and on-patent markets separately.
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Objectives: To identify what process and technology related characteristics influ-
ence reimbursement decisions in Ireland. MethOds: Using publically available 
data compiled from the NCPE and HSE websites from 2006 to 2013, we examined sev-
eral variables (disease area; transparency; and, assessment and judgement of effect 
and CE), as defined in Fischer (2013), to identify what influences reimbursement 
decisions made through the community drugs schemes (i.e. GMS, and High Tech 
schemes). Analyses included, Spearman’s Rank Correlation (SRC), Kruskal-Wallis 
and Fishers exact tests in the univariate analyses, and a step-wise multivariate 
regression. Results: For technology features most disease areas were found not 
to have a significant influence on reimbursement decisions (SRC: max 0.30, Fishers 
Exact: p> 0.10; and, regression analysis p> 0.10). However, treatments for endocrine 
conditions were significant (p< 0.10). For process features the availability, quantity, 
and type of assessment information were strongly correlated with reimbursement 
decision (SRC: ≥ 0.73). Judgement of effect and cost-effectiveness were significant 
(p< 0.05), and the multivariate regression showed “transparency”, “judgement of 
effect” and “judgement of CE” to be statistically significant (odds ratios: 0.095, 
2.752, and 3.657 respectively; p< 0.10). cOnclusiOns: Overall, increased trans-
parency (i.e. publically available documentation of the decision rationale) has a 
negative influence on the likelihood of reimbursement. This can be explained by 
the Rapid Review process, whereby products are initially screened and selected for 
further HTA analysis. As expected, those not selected for HTA are more likely to 
be reimbursed, but have less documentation supporting the decision, introducing 
less transparency overall. Where a HTA has been conducted, judgement of effec-
tiveness and cost-effectiveness has strong positive influence on reimbursement, 
with cost-effectiveness being the strongest positive influence. Fisher (2013) found 
stakeholder involvement to be an important influence; this could not be tested in 
the Irish context as the numbers of stakeholders known to be involved are constant 
across all observations.
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Objectives: In France, a forecast growth rate in spending related to the list of 
expensive hospital drugs, funded in addition to DRG-based payment, is determined 
annually (2% in 2012). If hospitals exceed the rate, they will be controlled, based on 
the proper use of drugs. The objective is to question the relevance of this national 
growth rate as a regulation tool. MethOds: This study used 2011/2012 data from 
“medicalized information system program”. Expensive drug expenditures are 
aggregated by each type of French hospitals (without private sector): cancer cent-
ers (CC= 19), university hospitals (UH= 32), hospitals centers (HC= 415) and private 
non-profit hospitals (PNPH= 104). In order to identify their specificities, we analyzed 
the expenditures of the first therapeutic class in value by hospital type and how 
much the top 3 drugs, that drive the overall growth, contribute to their respective 
growth. Results: Overall spending grew by 4.95% in 2012. Antineoplastic drugs (1% 
of decrease) represent 48% of overall expenditures. Their market share varies from 
34% in UH expenditures to 95% in CC, the only hospital type that meet the forecast 
rate. The top 3 drugs (2 immunosuppressant drugs and 1 replacement enzyme; 
17% of overall expenditures) contribute to 3.93 points of the total growth. Their 
contribution to the growth of each hospital types is uneven: from -0.02 point out of 
-6% in CC to 5.35 points out of 9.03% in UH. cOnclusiOns: There is a divergence 
in the growth of spending for the different hospital types because of their specific 
characteristics leading to different consumption profiles. Therefore, some hospitals 
are more impacted by changes in the spending structure, as CC for antineoplastic 
drugs. A regulation by an annual growth rate is useful because of its flexibility. But 
relevance of a single national rate does not reflect the care’s offer heterogeneity 
and needs local analyses.
